Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Lignende værker

• Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
  af: Ulrika Andersson, et al.
  Udgivet: (2004-08-01)
• NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
  af: Jeyakumar, M, et al.
  Udgivet: (2004)
• N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
  af: Andersson, U, et al.
  Udgivet: (2000)
• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
  af: Baek, R, et al.
  Udgivet: (2004)
• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
  af: Baek, R, et al.
  Udgivet: (2008)